ArticleCardiovascular diabetology2025
Association between the C-reactive protein-triglyceride glucose index and new-onset coronary heart disease among metabolically heterogeneous individuals.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed.
- Association of the C-reactive protein-triglyceride-glucose index (CTI) with lower-extremity peripheral artery disease among U.S. adults.Atherosclerosis plus · 2026Article
- C-reactive protein-triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with H-type hypertension.Cardiovascular diabetology · 2026Article
- Association of high-sensitivity C-reactive protein-triglyceride glucose index and stroke outcomes: results from the China National Stroke Registry III.BMC neurology · 2026Article
- Prognostic value of C-reactive protein-triglyceride-glucose index in hospitalised patients with acute decompensated heart failure.BMC cardiovascular disorders · 2026Article
- Relationship between hs-CRP-triglyceride glucose index and coronary plaque morphology: insights from optical coherence tomography.Diabetology & metabolic syndrome · 2026Article
- Associations between the C-reactive protein-triglyceride-glucose index and its derived indices and the incidence and progression of cardiometabolic multimorbidity in participants with metabolic dysfunction-associated steatotic liver disease: a large-scale prospective cohort study.Cardiovascular diabetology · 2026Article
- Remnant cholesterol inflammation index may be a superior biomarker to C-reactive protein-triglyceride glucose index in predicting carotid atherosclerosis risk.BMC endocrine disorders · 2026Article
- Association of the C-reactive protein-triglyceride-glucose (CTI) index and its central obesity-modified derivatives with incident cardiometabolic multimorbidity: results from two prospective cohorts in China and England.Cardiovascular diabetology · 2026Article
- Association of cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose and its modified indices with cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a longitudinal analysis based on CHARLS.Cardiovascular diabetology · 2026Observational
- Association of Serum Calprotectin and the C-Reactive Protein-Triglyceride-Glucose Index with SYNTAX Score in Patients with Newly Diagnosed Coronary Artery Disease.Medicina (Kaunas, Lithuania) · 2026Article
- C-reactive protein-triglyceride glucose index as a predictor of heart failure risk in adults with MASLD: a prospective cohort study.Scientific reports · 2026Article
- Metabolic status modifies the predictive value of the C-reactive protein-triglyceride-glucose Index-waist-to-height ratio for major adverse cardiovascular and cerebrovascular events: a prospective cohort study from the China Health and Retirement Longitudinal Study (CHARLS).Cardiovascular diabetology · 2026Article
- Associations of cumulative exposure and dynamic patterns of the C-reactive protein-triglyceride-glucose index with cardiometabolic multimorbidity in middle-aged and elderly Chinese: a nationwide cohort study.BMC public health · 2026Article
- Cumulative exposure and dynamic trajectories of the C-reactive protein-triglyceride-glucose index (CTI) versus the cholesterol, high-density lipoprotein, and glucose index (CHG) for incident hypertension prediction: a national cohort study.Cardiovascular diabetology · 2026Article
- Association of the C-reactive protein-triglyceride glucose index with all-cause and cardiovascular mortality among U.S. adults with metabolic dysfunction-associated steatotic liver disease: a national cohort study.Cardiovascular diabetology · 2026Article
- Association between triglyceride-glucose index and related indicators with heart failure-related mortality in individuals with early-stage cardiovascular-kidney-metabolic syndrome.Cardiovascular diabetology · 2026Article
- Association between C-reactive protein-triglyceride-glucose index and risk of stroke in different renal function status: a national cohort study.Cardiovascular diabetology · 2026Article
- Prognostic stratification with composite insulin resistance-inflammation biomarkers in patients with chronic kidney disease and coronary artery disease across glycemic statuses.Cardiovascular diabetology · 2026Article
- The Role of the C-Reactive Protein-Triglyceride Glucose Index in Predicting New-Onset Chronic Diseases: Evidence From a Longitudinal Cohort Study.Brain and behavior · 2026Article
- The association of C-reactive protein-triglyceride-glucose index with cardiometabolic multimorbidity in middle-aged and older adults: evidence from two cohort studies.Cardiovascular diabetology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe C-reactive protein-triglyceride glucose index (CTI) integrates inflammatory and metabolic markers and is closely associated with the incidence of coronary heart disease (CHD) and hypertension. However, its clinical utility among metabolically heterogeneous populations remains unclear. This study aims to investigate the association between CTI and new-onset CHD and to assess the potential value of combining CTI with the C-reactive protein-albumin-lymphocyte (CALLY) index in improving the identification of such clinical diagnoses.
methodsThis study included 2237 participants, categorized into four obesity and metabolic phenotypes: metabolically healthy normal weight, metabolically healthy overweight/obese, metabolically unhealthy normal weight (MUNW), and metabolically unhealthy overweight/obese. The association between the CTI and new-onset CHD was analyzed using logistic regression, accounting for potential confounders. Subgroup analyses stratified by glucose metabolic states, age, and gender were performed, and multiple statistical methods were further employed to investigate the mediating role of the CALLY index and the incremental value of CTI in combination with the CALLY index for enhancing the identification of new-onset CHD.
resultsThe analysis demonstrated a robust association between the CTI and new-onset CHD (P < 0.001), with the highest sensitivity observed in MUNW individuals. The CALLY index was identified as a partial mediator of this relationship, emphasizing the critical role of immune-inflammatory processes in CHD. Notably, individuals with a high CTI (≥ 9.887) and a low CALLY index (< 1.221) showed the strongest association with CHD diagnoses at admission (OR = 2.36, 95% CI: 2.06-2.69). The integration of the CTI and CALLY indices was significantly associated with a stronger discriminatory ability for new-onset CHD.
conclusionThe CTI demonstrated a significant statistical association with new-onset CHD diagnoses among metabolically heterogeneous individuals. Its combination with the CALLY index further enhanced diagnostic discrimination, supporting its potential utility in individualized identification and refined clinical assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.